Unique Immunotherapy platform

Our proprietary B cell–mediated immunotherapy platform elicits polyclonal antibodies against multiple disease-associated ligands - enabling broader and deeper therapeutic responses.

Our novel immunotherapy approach allows for better tolerability, reduced resistance to treatment, and no ADA concerns - thus increasing therapeutic options for patients

Efficacy & Long-term safety

A first-generation vaccine demonstrated significant clinical benefits in non-small cell lung cancer (NSCLC), with results validated in both clinical trials and real-world settings, including successful implementation in Cuba.

Our patented next-generation technology builds on this approach, offering enhanced potency, improved CMC/manufacturing profiles, strong IP, and expanded multi-targeting capabilities.

More...

Technology

Our proprietary technology platform enables the design of novel fusion molecules that combine our patented synthetic carrier construct with multiple antigens targeting specific proteins of interest. This approach breaks immune tolerance, stimulating the production of polyclonal antibodies that transiently deplete overexpressed ligands and cytokines, restoring them to normal physiological levels.

Technology governed by global foundational patents that generate compositon of matter and usage patents for pipeline assets

Graphic - IM injection breaking immune tolerance

Graphic showing targeting of specific growth factor

Graphic showing tumor inactivaton through ligand depletion

Pipeline

Multiple assets with shared platform and manufacturing process; indications spanning oncology, autoimmune disorders, and application in others (including neurodegeneration, metabolic, and bone disease)

Team

Global team of biotech executives and drug developers with experience in building biotech companies and succesfully taking multiple drugs into and through the clinic